A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults
Stephen J. Thomas(Global Viral), Bruce L. Innis(Universidad de Los Andes, Chile), Stefan Fernandez(Armed Forces Research Institute of Medical Science), Jean‐François Toussaint(Université Paris Cité), Kenneth H. Eckels(Walter Reed Army Institute of Research), Robert Putnak, Robert V. Gibbons, Francis Dessy(GlaxoSmithKline (Belgium)), Kristen M. Bauer, Rafael De La Barrera(Walter Reed Army Institute of Research), Wellington Sun, Isabelle Carletti
Cited by 97
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
|New England Journal of Medicine|2021|937
Rapid development of a DNA vaccine for Zika virus
|Science|2016|402
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
|New England Journal of Medicine|2015|390
Bluetongue virus detection by two real-time RT-qPCRs targeting two different genomic segments
|Journal of Virological Methods|2006|342